论文部分内容阅读
目的:研究替莫唑胺联合放疗治疗胶质母细胞瘤的成本-效果。方法:根据临床试验(EORTC26981/22981-NCIC CE3)数据,结合我国医疗费用及消费水平,进行成本-效果分析,并对结果进行敏感度分析。结果:替莫唑胺联合放疗方案相较于单纯放疗方案,每例患者总生存期增加1个月,需多花费人民币58 959.7元。结论:替莫唑胺联合放疗方案相对于单纯放疗方案不具有成本-效果优势。
Objective: To study the cost-effectiveness of temozolomide combined with radiotherapy in the treatment of glioblastoma. Methods: According to the data of clinical trial (EORTC26981 / 22981-NCIC CE3), combined with the medical expenses and consumption level in China, the cost-effectiveness analysis was carried out, and the sensitivity of the results was analyzed. Results: Temozolomide combined with radiotherapy compared with radiotherapy alone, the overall survival of each patient increased by 1 month, need to spend 58,959.7 yuan more. CONCLUSION: Temozolomide combined with radiotherapy has no cost-benefit advantage over radiotherapy alone.